Given these constraints, a key metric for success in this trial is the ULCIP’s ability to deliver the insulin dosage as prescribed by the diabetes clinician and indicated by observed changes in patients’ blood values aligning with the expected outcomes of the insulin delivery. This evidence concerns the gene INS and diabetes mellitus.